A class I innovative drug with global patent developed by frontier biology is the only long-acting anti-AIDS drug in the world, which has many global competitive advantages such as high safety, strong curative effect and convenient treatment. The listing of this product will fill the gap of new anticancer drugs in China. Compared with similar products listed abroad at present, Aibo Weitai also has distinct characteristics and market competitiveness. "Similar products need two shots a day, and our products only need one shot every two weeks. It is not only durable, but also has an obvious effect on cost control. " Wang Changjin, chief commercial officer of Frontier Biology, said.
It is understood that at present, tens of millions of yuan have been invested in the research and development of this drug, and about 654.38 billion yuan will be invested after starting the third phase of clinical practice.
From the establishment of the company in 2002 to the launch of new drugs in 20 12, it took 10 years. But these efforts will not be in vain. Aibo Weitai plans to launch the China market in 20 12, and conservatively estimates that the sales in that year can reach 1 100 million yuan; In the second year, it can jump to 200 million to 300 million yuan. Frontier biology will also jointly develop European and American markets with foreign pharmaceutical companies. In addition, there are 23 million AIDS-infected people in Africa, which will be an important market for Aibo Weitai, with annual sales reaching more than 654.38 billion yuan.
The reporter learned that the core team members of cutting-edge biology are almost all doctors. Chairman Xie Dong is a doctor of science and a postdoctoral fellow at Johns Hopkins University, CEO He Jiang is a doctor of medicine and a doctor of science, and Chief Commercial Officer Wang Changjin is a doctor of science at the School of Pharmacy of the University of Kentucky.
20 10 10, frontier biology became the first academician workstation unit in China. Ceng Yi, a famous virus expert and academician of Chinese Academy of Sciences, and Professor Jin Ronghua, dean of Beijing You 'an Hospital and a famous clinical medical expert, became the first batch of academician experts. This first academician workstation in Chongqing, which is married to an enterprise, combines the innovative R&D capability of the enterprise with the top domestic scientific and technological resources and becomes a "new engine" to enhance the core competitiveness.